1. Home
  2. SKLZ vs IFRX Comparison

SKLZ vs IFRX Comparison

Compare SKLZ & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skillz Inc.

SKLZ

Skillz Inc.

HOLD

Current Price

$5.73

Market Cap

95.0M

Sector

Technology

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.07

Market Cap

86.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKLZ
IFRX
Founded
2012
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.0M
86.0M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
SKLZ
IFRX
Price
$5.73
$1.07
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$14.00
$8.50
AVG Volume (30 Days)
53.0K
6.5M
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$92,256,000.00
$73,729.00
Revenue This Year
$13.33
N/A
Revenue Next Year
$12.68
$1,075.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.54
$0.71
52 Week High
$9.11
$2.77

Technical Indicators

Market Signals
Indicator
SKLZ
IFRX
Relative Strength Index (RSI) 46.02 42.82
Support Level $5.27 $1.04
Resistance Level $5.87 $1.12
Average True Range (ATR) 0.28 0.10
MACD 0.09 -0.01
Stochastic Oscillator 80.99 38.45

Price Performance

Historical Comparison
SKLZ
IFRX

About SKLZ Skillz Inc.

Skillz Inc is a mobile game development company. It is engaged in re-inventing competitive mobile gaming and thereby expanding the mobile gaming market. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The company's reportable business segments are; the Skillz segment and the Aarki segment. The majority of its revenue is generated from the Skillz segment which is an eSports gaming platform, enabling game developers to monetize their content through multi-player competition. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: